Troriluzole Fails First Phase III Test As Biohaven Looks Beyond Migraine

 
• By Mandy Jackson

Biohaven is still studying its glutamate modulator in three other indications, but its biggest near-term milestone will be approval of the oral CGRP inhibitor rimegepant for acute migraine.

Closed up finger on keyboard with word CLINICAL TRIALS
Troriluzole failed in anxiety, but has three other readouts in 2020 and 2021.

More from Clinical Trials

More from R&D